Bryan Czyzewski

Aegerion Pharmaceuticals: Capitalize on Cholesterol

Here's something I just noticed: if apoB levels are the new biomarker to follow for CHD risk assesment as the Farmington Study is leaning towards, then Isis' mipomersen and ezetimibe combo AEGR-733 both shoot it down 40 and 27 percent respectively. Now which would you rather take, an injection once a week as is necessary with Isis or a pill a day as in Aegerion's formulation.

Aegerion Pharmaceuticals: Capitalize on Cholesterol

Aegerion is trying to enter a very crowded market, true, but the combination market has some room, and this is where AEG-733 could really shine.